FAEE Stock Overview
Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and markets pharmaceutical products and raw materials in Spain and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Faes Farma, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.20 |
| 52 Week High | €3.80 |
| 52 Week Low | €3.07 |
| Beta | 0.52 |
| 1 Month Change | 0% |
| 3 Month Change | 3.57% |
| 1 Year Change | -15.92% |
| 3 Year Change | -8.84% |
| 5 Year Change | -12.29% |
| Change since IPO | 62.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| FAEE | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | 0.5% |
| 1Y | -15.9% | -4.8% | -0.1% |
Return vs Industry: FAEE underperformed the UK Pharmaceuticals industry which returned -7.1% over the past year.
Return vs Market: FAEE underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| FAEE volatility | |
|---|---|
| FAEE Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: FAEE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine FAEE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 1,764 | n/a | faesfarma.com |
Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and markets pharmaceutical products and raw materials in Spain and internationally. The company's products include prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn’s disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu.
Faes Farma, S.A. Fundamentals Summary
| FAEE fundamental statistics | |
|---|---|
| Market cap | €1.00b |
| Earnings (TTM) | €89.64m |
| Revenue (TTM) | €468.68m |
10.9x
P/E Ratio2.1x
P/S RatioIs FAEE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FAEE income statement (TTM) | |
|---|---|
| Revenue | €468.68m |
| Cost of Revenue | €160.06m |
| Gross Profit | €308.62m |
| Other Expenses | €218.98m |
| Earnings | €89.64m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.29 |
| Gross Margin | 65.85% |
| Net Profit Margin | 19.13% |
| Debt/Equity Ratio | 1.3% |
How did FAEE perform over the long term?
See historical performance and comparison